Latest Articles

  • Brain Fog and Long Covid

    August 4, 2021

    Brain Fog and Long Covid Dr Steve Allder, Consultant Neurologist at Re:Cognition Health:   It is unknown who is most affected by cognitive complaints induced by Covid-19 […]

  • Long Covid Metro blog

    August 2, 2021

    Long Covid Metro blog   Brain Fog & Long Covid Consultant Neurologist Dr Steve Allder shares his insight with the Metro:   Dr Steve Allder was recently […]

  • Turning Point for Brain Injury in Contact Sport

    July 23, 2021

      Re:Cognition Health is delighted to read the  recommendations and insights published on 22 July 2021 by  the  Department for Digital, Media, Culture and Sport, the Drake […]

  • Biogen FDA Accelerated Approval Under Investigation

    July 20, 2021

      By Rigby Sampson On Friday 9th July, Janet Woodcock the Acting Commissioner of the FDA (and former Director of the Centre for Drug Evaluation and Research […]

  • Minimum

    June 25, 2021

      Pollution and the brain   Re:Cognition Health applaud new Fintech start up Minimum.eco dedicated to making carbon neutrality easily accessible to all businesses. Minimum enables businesses to calculate and offset the carbon footprint of its […]

  • Proactive Measures To Protect Against Dementia

    June 18, 2021

    Dr Emer MacSweeney was featured in the Daily Mail, exploring some of the proactive measures we can take to help protect against dementia. At Re:Cognition Health, we […]

  • The negative effects of working long hours

    June 15, 2021

    The negative effects of working long hours   According to a recent global study, 745,000 people died in the past 12 months, from heart disease or stroke […]

  • IS ADHD Over-Diagnosed in Children and Adolescents?

    June 10, 2021

    IS ADHD Over-Diagnosed in Children and Adolescents?   A recent study published in JAMA (Journal of the American Medical Association)  Network has revealed that Attention Deficit Hyperactivity […]

  • Aducanumab, what this means for the UK

    June 8, 2021

    Aducanumab, what this means for the UK        On Monday 7th June 2021 the USA approved the first medication, ever, to combat the underlying cause of Alzheimer’s Disease. Aducanumab, […]

  • Aducanumab receives FDA Approval

    June 8, 2021

    First Alzheimer’s treatment to slow disease progression receives FDA approval on 07 June 2021   Aducanumab, the first disease modifying treatment for Alzheimer’s disease, which was tested […]

1 2 7 8 9 10 11 22 23

Help us make a difference in cognitive health

Sign Up Now